Key result
Azeliragon causes no clinically meaningful QTcF prolongation at therapeutic doses.
Why the study?
Azeliragon is being evaluated for safety in mild Alzheimer's disease, requiring assessment of its potential QTc interval prolongation liability.
Does azeliragon cause clinically meaningful QTc prolongation in healthy volunteers and patients with Alzheimer's disease or Type 2 diabetes?
Does azeliragon cause clinically meaningful QTc prolongation in healthy volunteers and patients with Alzheimer's disease or Type 2 diabetes?
Azeliragon does not cause clinically meaningful QTc prolongation at therapeutic or supra-therapeutic doses based on integrated concentration-QTc modeling.
Answers are grounded in this paper and cite their sources.
Supports azeliragon use without QTc monitoring in Alzheimer's or T2D; confirms cardiac safety in integrated concentration-QTc meta-analysis.
Azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), is being evaluated in a pivotal Phase 3 study for efficacy and safety in patients with mild Alzheimer's disease (AD). A concentration-driven model-based analysis of the relationship between azeliragon plasma concentration and change in QTc was conducted as supported by ICH E14 Q&A updated, December 2015. 6236 simultaneous (within ±30 minutes) plasma concentration and 12-lead ECG data were available from 711 subjects, pooled from 5 studies in healthy volunteers, 2 studies in patients with mild-to-moderate AD, and one study in patients with Type 2 diabetes and persistent albuminuria. Placebo or azeliragon was administered as single doses from 5 to 65 mg or repeat doses from 5 to 60 mg QD. Nonlinear mixed effects modelling was conducted to describe azeliragon concentration-related changes in QT interval, after correcting for heart rate using Frederica's criteria (QTcF) and gender-related differences in baseline QTcF. Azeliragon-related changes in QTcF were predicted using two methods: simulations (which accounted for inter-individual variability and parameter uncertainty) and a less conservative, bias-corrected 90% confidence interval approach. A small, positive relationship between azeliragon plasma concentration and QTcF was noted with a slope of 0.059 msec/ng/mL. Simulations predicted mean (90% prediction interval) changes in QTcF of 0.733 msec (0.32–1.66 msec) with the Phase 3 dose (5 mg QD stead state, predicted Cmax 11.0 ng/mL (5.24–23.7 ng/mL)) and 4.32 msec (1.7–8.74 msec) at supra-therapeutic doses (20 mg QD steady state or 60 mg QD x 6d, predicted Cmax 66.0 ng/mL (26.5–122.9 ng/mL)). Bias-corrected upper 90% confidence intervals for therapeutic and supra-therapeutic doses are 0.88 msec and 5.01 msec, respectively. The model-based analysis shows a small, non-clinically meaningful, positive relationship between azeliragon plasma concentration and QTcF with a slope close to zero. Neither the prediction interval nor the upper bound of the 90% confidence interval reach 10 msec, thus demonstrating no clinically meaningful (i.e. >5 msec prolongation) drug-related effect on QTcF at expected therapeutic and supra-therapeutic doses of azeliragon.
No takes yet. Share an insight, caveat, or question.
Burstein et al. (2017) studied Healthy volunteers, mild-to-moderate Alzheimer's disease, and Type 2 diabetes (n=711). Azeliragon vs. Placebo was evaluated on Change in QTcF (slope of 0.059 msec/ng/mL). Azeliragon showed a non-clinically meaningful relationship between plasma concentration and QTcF, with predicted changes of 0.733 msec at therapeutic doses, well below the 10 msec threshold.
Synapse has enriched 10 related papers. Consider them for comparative context: